Trial · NCT02468830
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | Complete elimination of urinary incontinence:100% | 13 | Participants | |
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | Significant response > 90%- | 14 | Participants | |
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | Partial response: 50-89% | 25 | Participants | |
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | Failure < 50% | 6 | Participants | |
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | baseline | 150 | Inter-Quartile Range 125 to 200 | milliliter |
| Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron | Mirabegron | Final visit | 200 | Inter-Quartile Range 171 to 300 | milliliter |
| Number of Participants With Cardio Vascular Safety | Mirabegron | No variation:systolic ±20 mmHg in blood pressure | 58 | Participants | |
| Number of Participants With Cardio Vascular Safety | Mirabegron | No variation:Diastolic ±15 mmHg in blood pressure | 58 | Participants | |
| Improved Quality of Life Using the Patient Perception of Bladder Condition (PPBC) Scale | Mirabegron | baseline | 4.0 | Inter-Quartile Range 4.0 to 5.0 | units on a scale |
| Improved Quality of Life Using the Patient Perception of Bladder Condition (PPBC) Scale | Mirabegron | Final visit | 2.0 | Inter-Quartile Range 1.0 to 3.0 | units on a scale |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Mirabegron | Mirabegron | No change in heart rate over 20% | 58 | Participants | |
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Mirabegron | Mirabegron | No significant change in heart rate | 58 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02468830/results